If targeted therapies, generally small molecules or antibodies, have demonstrated the interest of blocking some specific molecular mechanisms of cancer cells to impact cancer progression, the use of immunotherapies has revolutionised the entire cancer treatment approach.
Indeed, training, stimulating and strengthening human body defences to fight against abnormal cell growth has provided the hope for safer treatments having a prolonged effect to reduce cancer burden.
Our aim is to offer effective cancer therapies by complementing existing standards of care and by working in synergy with current immune-checkpoints inhibitors.
Therapeutic cancer vaccines are administered to cancer patients in order to strengthen the capability of their immune system to recognise and kill tumour cells.
In order to allow cancer immunity to be initiated and for the induction of a potent tumour specific immune response, a therapeutic vaccine needs to fulfil the three parameters below.
AMAL’s KISIMA® immunisation platform combines all these into a single, novel proprietary cancer vaccine construct and is highly adaptable for a large spectrum of antigens and/or indications.